



July 10, 2026

Company: Ono Pharmaceutical Co., Ltd.
Representative: Toichi Takino
Representative Director, President and COO
(Securities Code: 4528 Prime market, TSE)
Contact: Ryuta Imura
Vice President, Corporate Communications
(Phone: +81-6-6263-5670)

Notice concerning Completion of Disposal of Treasury Shares as Tenure-based Restricted Stock Compensation and Performance-linked Restricted Stock Compensation

Osaka, Japan, July 10, 2026 - Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Toichi Takino; "the Company") today announced that the payment procedures were completed on July 10, 2026 as follows for disposal of treasury shares as tenure-based restricted stock compensation and performance-linked restricted stock compensation resolved at the Board of Directors meeting held on June 18, 2026. For more details, please refer to "Notice of Disposal of Treasury Shares as Tenure-based Restricted Stock Compensation and Performance-linked Restricted Stock Compensation" dated June 18, 2026.

Overview of Disposal of Treasury Shares

1. Disposal as tenure-based restricted stock compensation

(1) Disposal date	July 10, 2026
(2) Class and number of shares to be disposed of	20,900 shares of common stock of the Company
(3) Disposal price	2,249.5 yen per share
(4) Total value of shares to be disposed of	47,014,550 yen
(5) Allottees and number thereof; number of disposed shares	Board of Directors of the Company (excluding Outside Directors): 3 persons / 20,900 shares

2. Disposal as performance-linked restricted stock compensation

(1) Disposal date	July 10, 2026
(2) Class and number of shares to be disposed of	179,000 shares of common stock of the Company
(3) Disposal price	2,249.5 yen per share
(4) Total value of shares to be disposed of	402,660,500 yen
(5) Allottees and number thereof; number of disposed shares	Board of Directors of the Company (excluding Outside Directors): 3 persons / 94,500 shares Corporate Officers who are not the Board of Directors of the Company: 13 persons / 84,500 shares

Contact:

Ono Pharmaceutical Co., Ltd.
Corporate Communications
public_relations@ono-pharma.com